Zynerba Pharmaceuticals Announces Poster Presentations at the 22nd Society for the Study of Behavioural Phenotypes (SSBP) Sym...
August 29 2019 - 7:30AM
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in
innovative pharmaceutically-produced transdermal cannabinoid
therapies for rare and near-rare neuropsychiatric disorders, today
announced the acceptance and presentation details of two posters at
the 22nd Society for the Study of Behavioural Phenotypes
(SSBP) Symposium. The meeting is being held at Aston University in
Birmingham, UK on September 4th through 6th, 2019. The posters will
be viewable throughout September 5th and 6th and the authors will
be available for additional discussion at the poster at the times
noted below.
Poster title: “Content Validity of the
ABC-CFXS and Subscales in Fragile X Syndrome”Author
presentation time: 12:40PM – 1:45PM BST, September 5th and
6th, 2019This poster will describe information evaluating the
Social Avoidance, Irritability, and Socially Unresponsive/Lethargic
subscales of the Aberrant Behavior Checklist Community: FXS
Specific (ABC-CFXS) in relation to the experience of caregivers
caring for a child with Fragile X syndrome (FXS). In addition, the
poster will describe the most common core FXS behaviors from the
perspective of caregivers of children with the disorder.
Poster title: “Common Behavioral Features of Autism,
Fragile X Syndrome, and 22q11.2 Deletion Syndrome”Author
presentation time: 12:40PM – 1:45PM BST, September 5th and
6th, 2019Based on insights from Company data, Zynerba conducted a
retrospective literature review on patients with autism spectrum
disorder, FXS, and 22q11.2 deletion syndrome to determine the
symptomatic overlap between these disorders and to determine a
possible role for cannabidiol (CBD) in managing the spectrum of
behavioral symptoms associated with these conditions. The poster
will describe the results of this review.
About Zynerba Pharmaceuticals, Inc. Zynerba
Pharmaceuticals is the leader in pharmaceutically-produced
transdermal cannabinoid therapies for rare and near-rare
neuropsychiatric disorders. We are committed to improving the lives
of patients and their families living with severe, chronic health
conditions including Fragile X Syndrome, Autism Spectrum Disorder,
22q11.2 Deletion Syndrome, and a heterogeneous group of rare and
ultra-rare epilepsies known as developmental and epileptic
encephalopathies. Learn more at www.zynerba.com and follow us on
Twitter at @ZynerbaPharma.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should” or other words that convey uncertainty of
future events or outcomes to identify these forward-looking
statements. Such statements are subject to numerous important
factors, risks and uncertainties that may cause actual events or
results to differ materially from the Company’s current
expectations. These and other risks are described in the
Company’s periodic reports, including the annual report on Form
10-K, quarterly reports on Form 10-Q and current reports on Form
8-K, filed with or furnished to the Securities and Exchange
Commission and available at www.sec.gov. Any forward-looking
statements that the Company makes in this press release speak only
as of the date of this press release. The Company assumes no
obligation to update forward-looking statements whether as a result
of new information, future events or otherwise, after the date of
this press release.
Zynerba ContactWill Roberts, VP Investor
Relations and Corporate
Communications484.581.7489robertsw@zynerba.com
Media contactMolly DevlinEvoke
KYNE215.928.2199Molly.Devlin@evokegroup.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Apr 2023 to Apr 2024